Business, energy, technology, markets and global industry news from Business News Today

complicated urinary tract infections

PharmaDeviceNews complicated urinary tract infections
Representative image of an intravenous antibiotic vial and sterile hospital laboratory setup, reflecting Wockhardt’s Zaynich FDA approval and India’s growing role in antimicrobial resistance innovation.
Pharma & Biotech

Can Zaynich help Wockhardt turn Indian antibiotic innovation into a global commercial platform?

Find out how Wockhardt’s Zaynich FDA approval could reshape Indian pharma innovation and the fight against drug-resistant infections.

Read More
Representative image: A clinical research laboratory setting illustrates Meiji Seika Pharma’s nacubactam Phase III progress, as the novel β-lactamase inhibitor advances the fight against complicated urinary tract infections, acute pyelonephritis and antimicrobial resistance.
Pharma & Biotech

Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain

Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.

Read More